PatientsVille.com Logo

Glargine Side Effects

PatientsVille

Common Glargine Side Effects


The most commonly reported Glargine side effects (click to view or check a box to report):

Blood Glucose Decreased (4)
Blood Glucose Increased (4)
Hypoglycaemia (3)
Asthenia (3)
Cold Sweat (2)
Dehydration (2)
Chills (2)
Hyperhidrosis (2)
Myocardial Infarction (2)
Lethargy (2)
Abdominal Pain (1)
Coronary Artery Disease (1)
Diabetic Ketoacidosis (1)
Arthralgia (1)
Cough (1)
Blood Ketone Body (1)
Convulsion (1)
Confusional State (1)
Blood Potassium Increased (1)
Blood Glucose Fluctuation (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Glargine Side Effects Reported to FDA



Glargine Side Effect Report#8078858-7
Rash Papular, Rash Pruritic
This is a report of a 62-year-old female patient (weight: NA) from United States, suffering from the following health symptoms/conditions: diabetes mellitus,ankylosing spondylitis,hypertension,bipolar disorder,incontinence,blood cholesterol increased,herpes virus infection, who was treated with Glargine (dosage: In The Morning, start time: NS), combined with:
  • Humira
  • Lisinopril
  • Bupropion Hcl (2, Twice Daily)
  • Oxybutynine
  • Simvastatin (1/2 Tab Daily)
  • Acyclovir
  • Aspart (30 Units In The Morning + 20 Units At Lunch And Dinner)
  • Lasix
and developed a serious reaction and side effect(s): Rash Papular, Rash Pruritic after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Glargine treatment in female patients, resulting in Rash Papular side effect.
Glargine Side Effect Report#7547806-8
Subcutaneous Haematoma, Progressive Multifocal Leukoencephalopathy
This report suggests a potential Glargine Insulin Subcutaneous Haematoma side effect(s) that can have serious consequences. A 59-year-old female patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: diabetes mellitus and used Glargine Insulin (dosage: NA) starting
Mar 01, 2011. After starting Glargine Insulin the patient began experiencing various side effects, including: Subcutaneous Haematoma, Progressive Multifocal LeukoencephalopathyAdditional drugs used concurrently:
  • Tysabri
  • Simvastatin
  • Baclofen
  • Aspirin
  • Calcium Carbonate
  • Bisacodyl
  • Sliding Scale Insulin
  • Bisoprolol Fumarate
The patient was hospitalized. Although Glargine Insulin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Subcutaneous Haematoma, may still occur.
Glargine Side Effect Report#7444694-5
Muscular Weakness, Asthenia, Hypoaesthesia, Multiple Myeloma, Neoplasm Progression
This Muscular Weakness problem was reported by a pharmacist from United States. A 59-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Glargine (dosage: NA). The following drugs were being taken at the same time:
  • Lorazepam
  • Senna-mint Waf
  • Revlimid (10 Mg Daily X21d/28d Orally)
  • Novolin R
  • Morphine
  • Dexamethasone
  • Acyclovir
  • Docusate
When using Glargine, the patient experienced the following unwanted symptoms/side effects: Muscular Weakness, Asthenia, Hypoaesthesia, Multiple Myeloma, Neoplasm ProgressionAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Muscular Weakness, may become evident only after a product is in use by the general population.
Glargine Side Effect Report#7380736-3
Myocardial Infarction, Coronary Artery Disease
This Myocardial Infarction side effect was reported by a consumer or non-health professional from United States. A 49-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Glargine (drug dosage: NA), which was initiated on
Nov 13, 2001. Concurrently used drugs:
  • Aspirin
  • Lumigan
  • Avandia (4mg Per Day)
  • Glucotrol
  • Tricor
  • Pravachol
  • Glipizide
  • Altace
.After starting to take Glargine the consumer reported adverse symptoms, such as: Myocardial Infarction, Coronary Artery DiseaseThese side effects may potentially be related to Glargine. The patient was hospitalized.
Glargine Side Effect Report#7275894-5
Myocardial Infarction, Septic Shock
This is a report of a 59-year-old female patient (weight: NA) from United States, suffering from the following health symptoms/conditions: NA, who was treated with Glargine (dosage: NA, start time:
Dec 13, 1999), combined with:
  • Toprol-xl
  • Glucophage
  • Lipitor
  • Avandia (8mg Per Day)
and developed a serious reaction and side effect(s): Myocardial Infarction, Septic Shock after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Glargine treatment in female patients, resulting in Myocardial Infarction side effect. The patient was hospitalized.
Glargine Side Effect Report#6522094-X
Blood Glucose Decreased, Blood Glucose Increased, Night Sweats
This report suggests a potential Glargine Insulin Blood Glucose Decreased side effect(s) that can have serious consequences. A male patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: hyperglycaemia and used Glargine Insulin (dosage: 21 Units Sq Qhs) starting
Oct 19, 2009. After starting Glargine Insulin the patient began experiencing various side effects, including: Blood Glucose Decreased, Blood Glucose Increased, Night SweatsAdditional drugs used concurrently:
  • Aspart Insulin (6 Units Sq Tid Ac)
  • Apap Tab
  • Amiodarone Hcl
  • Bisacodyl
  • Cefepime
  • Cetirizine
  • Diltiazem
  • Diphenhydramine Docusate
The patient was hospitalized. Although Glargine Insulin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Blood Glucose Decreased, may still occur.
Glargine Side Effect Report#6379368-5
Blood Glucose Decreased, Blood Glucose Increased, Cold Sweat, Hyperhidrosis, Lethargy
This Blood Glucose Decreased problem was reported by a pharmacist from United States. A 55-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: type 1 diabetes mellitus. On
Nov 14, 2008 this consumer started treatment with Glargine Insulin (dosage: 60 Units). The following drugs were being taken at the same time:
  • Aspart (Ssi 2 Units Post Prenatal 30 Units)
  • Enoxaparin Sodium
  • Aspirin
  • Carvedilol
  • Atorvastatin
  • Clopidogrel
  • Enalapril Maleate
  • Lansiprazole
When using Glargine Insulin, the patient experienced the following unwanted symptoms/side effects: Blood Glucose Decreased, Blood Glucose Increased, Cold Sweat, Hyperhidrosis, LethargyAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Blood Glucose Decreased, may become evident only after a product is in use by the general population.
Glargine Side Effect Report#6377600-5
Asthenia, Blood Glucose Decreased, Blood Glucose Increased, Chills, Cough, Dyspnoea, Hypertensive Crisis, Lethargy
This Asthenia side effect was reported by a pharmacist from United States. A 56-year-old female patient (weight:NA) experienced the following symptoms/conditions: type 1 diabetes mellitus.The patient was prescribed Glargine (drug dosage: 16 Units Sq Q Pm, Pta), which was initiated on NS. Concurrently used drugs:
  • Aspirin
  • Irbesartan
  • Cincalet
  • Isosorbide
  • Labetalol Hcl
.After starting to take Glargine the consumer reported adverse symptoms, such as: Asthenia, Blood Glucose Decreased, Blood Glucose Increased, Chills, Cough, Dyspnoea, Hypertensive Crisis, LethargyThese side effects may potentially be related to Glargine. The patient was hospitalized.
Glargine Side Effect Report#5124625-3
Blood Glucose Fluctuation, Cold Sweat, Confusional State, Hyperhidrosis, Hypoglycaemia
This is a report of a female patient (weight: NA) from United States, suffering from the following health symptoms/conditions: diabetes mellitus insulin-dependent, who was treated with Glargine (dosage: 24 Units Once Daily Sq, start time:
Jan 01, 1994), combined with:
  • Humalog (2 Units With Meals With Meals Sq)
  • Acetaminophen
  • Maalox Fast Blocker
  • Carvedilol
  • Digoxin
  • Diltiazem Hcl
  • Rnoxaparin
  • Lexapro
and developed a serious reaction and side effect(s): Blood Glucose Fluctuation, Cold Sweat, Confusional State, Hyperhidrosis, Hypoglycaemia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Glargine treatment in female patients, resulting in Blood Glucose Fluctuation side effect. The patient was hospitalized.
Glargine Side Effect Report#5113679-6
Blood Glucose Decreased, Malaise, Oral Intake Reduced
This report suggests a potential Glargine Blood Glucose Decreased side effect(s) that can have serious consequences. A 88-year-old female patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: diabetes mellitus insulin-dependent and used Glargine (dosage: 10 U Sc Qhs) starting NS. After starting Glargine the patient began experiencing various side effects, including: Blood Glucose Decreased, Malaise, Oral Intake ReducedAdditional drugs used concurrently:
  • Glipizide (5 Mg Po Qd)
The patient was hospitalized. Although Glargine demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Blood Glucose Decreased, may still occur.
Glargine Side Effect Report#4945371-2
Arthralgia, Chills, Convulsion, Hypoglycaemia
This Arthralgia problem was reported by a pharmacist from United States. A 52-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: diabetes mellitus. On NS this consumer started treatment with Glargine Insulin (dosage: 56 Units Qhs Sc). The following drugs were being taken at the same time:
  • Aspart Insulin (12 Units Ac Bid Sc)
When using Glargine Insulin, the patient experienced the following unwanted symptoms/side effects: Arthralgia, Chills, Convulsion, HypoglycaemiaThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Arthralgia, may become evident only after a product is in use by the general population.
Glargine Side Effect Report#4796369-9
Abdominal Pain, Asthenia, Blood Glucose Increased, Blood Ketone Body, Blood Potassium Increased, Dehydration, Diabetic Ketoacidosis, Glucose Urine Present
This Abdominal Pain side effect was reported by a consumer or non-health professional from United States. A 50-year-old male patient (weight:NA) experienced the following symptoms/conditions: diabetes mellitus insulin-dependent.The patient was prescribed Glargine Insulin (drug dosage: 120 U Sq Qhs), which was initiated on NS. Concurrently used drugs: NA..After starting to take Glargine Insulin the consumer reported adverse symptoms, such as: Abdominal Pain, Asthenia, Blood Glucose Increased, Blood Ketone Body, Blood Potassium Increased, Dehydration, Diabetic Ketoacidosis, Glucose Urine PresentThese side effects may potentially be related to Glargine Insulin. The patient was hospitalized.
Glargine Side Effect Report#4646765-5
Dehydration, Dizziness, Fall, Hypoglycaemia
This is a report of a 71-year-old male patient (weight: NA) from , suffering from the following health symptoms/conditions: diabetes mellitus, who was treated with Glargine Insulin (dosage: 40u Qam Subcutaneo, start time:
Feb 01, 2005), combined with: NA. and developed a serious reaction and side effect(s): Dehydration, Dizziness, Fall, Hypoglycaemia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Glargine Insulin treatment in male patients, resulting in Dehydration side effect. The patient was hospitalized.



The appearance of Glargine on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.

Track Your Side Effects

Note Your Observations

It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    Glargine reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
    FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

    Discuss Glargine Side Effects

    Did You Have a Glargine Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Glargine for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Glargine Safety Alerts, Active Ingredients, Usage Information

    More About Glargine

    Side Effects reported to FDA: 13

    Glargine safety alerts: 2009

    Reported deaths: 2

    Reported hospitalizations: 5

    Lantus (insulin glargine)

    Audience - Diabetes healthcare professionals, patients

    [UPDATED 01/12/2011] FDA has reviewed studies and determined that the evidence presented in the studies is inconclusive, due to limitations in how the studies were designed and carried out and in the data available for analysis. These limitations prevent ability to attribute the observed cancer risk to Lantus.

    At this time, FDA has not concluded that Lantus increases the risk of cancer. FDA's review is ongoing, including review of information from a current clinical trial, and the Agency will update the public when it has additional information. 

    • Healthcare professionals should continue to follow the recommendations in the drug label when prescribing Lantus.
    • Patients should continue taking Lantus unless told otherwise by their healthcare professional.
    For more information on FDA's review, please refer to the January 12 2011 Drug Safety Communication.

     

    [Posted 07/01/2009] FDA notified healthcare professionals and patients that it is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus. Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood sugar levels can have both immediate and long-term serious adverse effects.

    FDA is currently reviewing many sources of safety data for Lantus, including these newly published observational studies, data from all completed controlled clinical trials, and information about ongoing controlled clinical trials, to better understand the risk, if any, for cancer associated with use of Lantus. Discussions are also ongoing between FDA and the manufacturer of Lantus as to whether any additional studies evaluating the safety and efficacy of this drug will need to be performed. FDA will communicate the results on its ongoing review to the public, as appropriate, as our review continues.

    The FDA encourages both healthcare professionals and patients to report side effects from the use of insulin glargine to the FDA's MedWatch Adverse Event Reporting Program.

     

    [01/12/2011 - Drug Safety Communication - FDA]
    [07/01/2009 - Early Communication About Safety of Lantus (insulin glargine) - FDA]

    Latest Glargine clinical trials